ImmuneOnco Succesfully Finished First-in-Human Dosing of Its Bi-Specific Fusion Protein IMM2510

August 18, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that first-in-human (FIH) dosing of IMM2510, the second product of bi-specific antibodies in clinical stage, has been......

2021-08-19

Investigational New Drug (IND) application for the product of bispecific CD47xHer2 accepted by the US Food and Drug Administration (FDA)

Shanghai, China, July 28, 2021 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted an IND application for the first-in-class bispecific antibody-receptor recombinant protein (IMM2902)......

2021-07-28

Tracy Song appointed as Chief Financial Officer (CFO) of ImmuneOnco

Shanghai, China, July 26, 2021 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that Ms.Tracy(Ziyi) Song has been appointed as the Chief Financial Officer (CFO) of the company, reporting to Dr.......

2021-07-27

New Milestone: The Bi-specific CD47XHER2 fusion protein, IMM2902 approved for clinical trial by National Medical Products Administration (NMPA)

June 30, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first-in-Class drug candidate, Bi-specific recombinant fusion protein targeting human CD47and HER2 named IMM2......

2021-07-01

ImmuneOnco Held 2021 Shareholders’ Conference

June 16, 2021, Shanghai, China ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") 2021 annual meeting of shareholders was successfully held at "47" Building, Lane 908, Ziping Road. The founder and chairman of Imm......

2021-06-17